OncoMatch/Clinical Trials/NCT06824064
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
Is NCT06824064 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies RBS2418 for metastatic colorectal cancer.
Treatment: RBS2418 — RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation. The hypothesis is that RBS2418 versus placebo will be generally safe, well-tolerated, immunogenic, and will lead to anti-tumor responses in adult subjects for the treatment of advanced, metastatic, and progressive colorectal cancer (CRC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Colorectal Cancer
Disease stage
Required: Stage IV, PROGRESSIVE
Metastatic disease required
advanced, metastatic, progressive CRC
Prior therapy
Must have received: all approved standard of care therapies for metastatic CRC — metastatic
have received, been ineligible for, intolerant to, or declined all approved standard of care (SOC) therapies for metastatic CRC
Cannot have received: any approved anti-cancer therapy including chemotherapy, targeted small molecule therapy, systemic immunotherapy, or radiation therapy
Exception: palliative radiotherapy for bone metastases or soft tissue lesions completed >7 days prior; hormone-replacement therapy or oral contraceptives; subjects with Grade 2 neuropathy or Grade 2 alopecia
Any approved anti-cancer therapy including chemotherapy, targeted small molecule therapy, systemic immunotherapy, or radiation therapy within 2 weeks prior to the first dose of study treatment; or if subject has not recovered (i.e., ≤ to Grade 1 or returned to baseline level) from AEs due to a previously administered agent; the following exceptions are allowed: * Palliative radiotherapy for bone metastases or soft tissue lesions should be completed >7 days prior to the first dose of study treatment. * Hormone-replacement therapy or oral contraceptives. * Subjects with Grade 2 neuropathy or Grade 2 alopecia.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Community Clinical Trials · Kingwood, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06824064 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior any approved anti-cancer therapy including chemotherapy, targeted small molecule therapy, systemic immunotherapy, or radiation therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV or PROGRESSIVE is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages